Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Bioavailability of Obexelimab (XmAb5871) in Healthy Volunteers
NCT02867098Phase 1Completed
- Sponsor
- Xencor
- Start
- Jul 2016
- Primary completion
- Oct 2016
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of obexelimab in IgG4-related disease (IgG4-RD) and systemic lupus erythematosus (SLE) (5 cohorts), sponsored by Xencor. Primary endpoints: Maximum observed serum concentration at Day 57, Time of maximum observed serum concentration at Day 57 and 8 more. Started Jul 2016; status: completed.
02
Drugs
obexelimab
03
Conditions
IgG4-related disease (IgG4-RD)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02867098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02867098.